سعر Xarelto 2.5 mg 56 f.c. tab 2026
- المادة الفعالة: Rivaroxaban
- Bayer Healthcare
- عن طريق الفم
الفئة: مضاد للتخثر
دواعي استعمال Xarelto 2.5
- In combination with aspirin, to reduce the risk of major cardiovascular events (CV death, MI, stroke) in coronary artery diseaseالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- In combination with aspirin, to reduce the risk of major thrombotic vascular events in peripheral artery disease, including after lower-extremity revascularizationالفئة: AdultsDailyMed (U.S. National Library of Medicine)
- In combination with aspirin, to reduce the risk of major cardiovascular events (CV death, MI, stroke) in coronary artery diseasePopulation: AdultsDailyMed (U.S. National Library of Medicine)
- In combination with aspirin, to reduce the risk of major thrombotic vascular events in peripheral artery disease, including after lower-extremity revascularizationPopulation: AdultsDailyMed (U.S. National Library of Medicine)
معلومات الدواء
التفاصيل الكاملةالآثار الجانبيةSide effects
- The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
- Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
تابع أسعار الأدوية أول بأول
بننشر كل يوم أسعار أدوية اتغيرت والبدائل الأرخص
المثائل (7)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| Xanoxiban 2.5 mg 10 f.c. tabs.Hikma Pharma · أقراص مغلفة · 2.5 mgالأرخص | السعر32.25ج.م3.23ج.م للوحدة | الفرق عن الأصليأرخص 1,141.75ج.م (97.3%) |
| اندوريفابان 2.5 مجم 20 قرصAndorivaban 2.5 mg 20 f.c. tabsAndalous Pharma · قرص مغلف · 2.5 mg per tablet | السعر64ج.م3.2ج.م للوحدة | الفرق عن الأصليأرخص 1,110ج.م (94.5%) |
| ريفاروسبير 2.5مجم 20 قرصRivarospire 2.5 mgInspire Pharmaceutical Company · 2.5 mg | السعر66ج.م3.3ج.م للوحدة | الفرق عن الأصليأرخص 1,108ج.م (94.4%) |
| ريباتوكسابان 2.5مجم 30 قرصRepatoxaban 2.5 mg 30 tabsEva Pharma · 2.5 mg | السعر96.75ج.م3.23ج.م للوحدة | الفرق عن الأصليأرخص 1,077.25ج.م (91.8%) |
| فاكساتو 2.5مجم 30 قرصVaxato 2.5mg 30 tabsLiptis · أقراص مغلفة · 2.5 mg | السعر96.75ج.م3.23ج.م للوحدة | الفرق عن الأصليأرخص 1,077.25ج.م (91.8%) |
تاريخ السعر
تغيّر السعر الرسمي: من 903 إلى 1,174 ج.م، 2 أسعار مسجلة
| التاريخ | السعر (ج.م) |
|---|---|
| سعر سابق بدون تاريخ | 903 |
| 1,174 |
| التاريخ | من | إلى | التغيير |
|---|---|---|---|
| 903ج.م | 1,174ج.م | زيادة 30% |
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Bayer Healthcare
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
- European Medicines Agency
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا